Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 595

Results For "ENT"

9427 News Found

Venus Remedies receives approval to market meropenm in Spain
News | June 23, 2023

Venus Remedies receives approval to market meropenm in Spain

The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries


GenWorks Health launched GenStore
Digitisation | June 23, 2023

GenWorks Health launched GenStore

GenWorks has scaled up its e-commerce platform in terms of building traffic


Polyplastics announces commercial availability of DURACON POM PM Series for medical industry
News | June 23, 2023

Polyplastics announces commercial availability of DURACON POM PM Series for medical industry

The company will supply materials to all global regions including Asia such as China, India, Europe, and the U.S.


Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states
News | June 22, 2023

Mandaviya reviews preparedness to the ongoing heat wave in 7 affected states

Effective disaster response and management is a collaborative work


Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler
Drug Approval | June 22, 2023

Lupin receives USFDA approval for Tiotropium Dry Powder Inhaler

This product will be manufactured at Lupin's Pithampur facility in India


Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases
News | June 21, 2023

Lupin signs MoU with Govt. of Maharashtra to combat rising prevalence of cardiovascular diseases

The partnership aims to prioritize the diagnosis and treatment of these diseases while working to reducing their long-term prevalence


Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals
News | June 21, 2023

Nouryon launches new high-efficiency spherical silica for peptide-based pharmaceuticals

This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments